                               SEQUENCE LISTING

<110> SAREPTA THERAPEUTICS, INC.
 
<120> PEPTIDE OLIGONUCLEOTIDE CONJUGATES

<130> 586558: SPT-002PC

<140>
<141>

<150> 62/267,723
<151> 2015-12-15

<160> 12    

<170> PatentIn version 3.5

<210> 1
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE 
<222> (1)..(1)
<223> Acetylation

<400> 1
Arg Arg Arg Arg Arg Arg Gly 
1               5           


<210> 2
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      morpholino oligonucleotide


<220>
<221> misc_feature
<222> (1)..(18)
<223> Morpholino-based oligomer; nucleotide moieties according to Table
      1

<220>
<221> misc_feature
<222> (1)..(18)
<223> Phosphoramidate or phosphorodiamidate linkage between nucleotides

<400> 2
gctattacct taacccag                                                     18


<210> 3
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      morpholino oligonucleotide


<220>
<221> misc_feature
<222> (1)..(19)
<223> Morpholino-based oligomer; nucleotide moieties according to Table
      1

<220>
<221> misc_feature
<222> (1)..(19)
<223> Phosphoramidate or phosphorodiamidate linkage between nucleotides

<400> 3
gctattacct taacccagt                                                    19


<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE 
<222> (1)..(1)
<223> Acetylation

<220>
<221> MOD_RES
<222> (6)..(6)
<223> Arg-APA

<400> 4
Arg Arg Arg Arg Arg Arg 
1               5       


<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE 
<222> (1)..(1)
<223> Acetylation

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Gly-PIP-PEG3

<400> 5
Arg Arg Arg Arg Arg Arg Gly 
1               5           


<210> 6
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE 
<222> (1)..(1)
<223> Acetylation

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Gly-PEG4

<400> 6
Arg Arg Arg Arg Arg Arg Gly 
1               5           


<210> 7
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE 
<222> (1)..(1)
<223> Acetylation

<220>
<221> MOD_RES
<222> (7)..(7)
<223> Gly-PEG8

<400> 7
Arg Arg Arg Arg Arg Arg Gly 
1               5           


<210> 8
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE 
<222> (1)..(1)
<223> Acetylation

<220>
<221> MOD_RES
<222> (1)..(6)
<223> D-amino acid

<400> 8
Arg Arg Arg Arg Arg Arg Gly 
1               5           


<210> 9
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 9
caatgtttct ggatgcagac tttgtgg                                           27


<210> 10
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 10
gttcagcttc actctttatc ttctgcc                                           27


<210> 11
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 11
cacatctttg atggtgtgag g                                                 21


<210> 12
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 12
caacttcagc catccatttc tg                                                22


